Companies /Healthcare

Atricure Inc

NASDAQ: ATRC Medical Instruments & Supplies
$56.84
▲ $0.86 (+1.54%) today
Markets closed · 12:06pm ET

ATRC at a Glance

Valuation
Market cap
$2.9B
P/E ratio
183.4
Profitability
Revenue (TTM)
$589.8M
Profit margin
2.5%
EPS (TTM)
$0.31
Price
52-week range
$25 – $66
Street target
$64.89

Headquartered in Mason, OH Fiscal year ends December NASDAQ: ATRC atricure.com

About AtriCure

AtriCure, Inc. is a medical device company focused on surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management.

It sells products in the United States and internationally, through direct sales and independent distributors, across four franchises:
- Open ablation: the Isolator Synergy Ablation System, the first medical device to receive FDA approval for treating persistent Afib, and the EnCompass clamp.
- Minimally invasive ablation: Hybrid AF Therapy for long-standing persistent Afib.
- Appendage management: the AtriClip LAA Exclusion System, including the FLEX-Mini and PRO-Mini devices.
- Pain management: cryoICE cryoSPHERE (including cryoSPHERE MAX) and cryoXT probes, cleared for temporary ablation of peripheral nerves to block pain in cardiac, thoracic and amputation procedures.

The company is running the BoxX-NoAF clinical trial. Its minimally invasive ablation business faces pressure as physicians adopt pulsed field ablation (PFA) catheters. Updated

Latest Activity

ATRCAtriCure
Q3 2026
EPS
$0.17
est $0.01+$0.16
Revenue
$154M
est $151M+2.2%

A company Wall Street expected to barely break even just delivered adjusted EPS of $0.17, beating expectations. Management now sees full-year revenue of $606 million to $610 million, so the profitability turn in cardiac ablation and pain management is no longer a one-quarter fluke.

Quarterly EPS — reported vs estimate
  • ABTAbbott Laboratories Common Stock (ABT)Buy$1K – $15KSep 18
  • AEIS150 Main Street Trust > Bank of America Advanced Energy Industries, Inc. - CommoBuy$1K – $15KSep 29
  • ALKS150 Main Street Trust > Bank of America Alkermes plc - Ordinary Shares (ALKS)Buy$1K – $15KSep 29
  • ALGM150 Main Street Trust > Bank of America Allegro MicroSystems, Inc. - Common StocBuy$1K – $15KSep 29
  • APP150 Main Street Trust > Bank of America Applovin Corporation - Class A Common StBuy$1K – $15KSep 18
  • ATRC150 Main Street Trust > Bank of America AtriCure, Inc. - Common Stock (ATRC)Partial sell$1K – $15KSep 29
  • BCPCBalchem Corporation - Common Stock (BCPC)Buy$1K – $15KSep 17
  • BHE150 Main Street Trust > Bank of America Benchmark Electronics, Inc. Common StockBuy$15K – $50KOct 1
+ 49 more trades in this filing
Made public 39 days after the earliest trade

A former Pentagon undersecretary just disclosed 57 trades in one filing, with the heaviest buying in semiconductors and electronics manufacturing: NXP, ON Semiconductor and Benchmark Electronics all picked up in size. The disclosure landed 39 days after the earliest trade.

ATRC Coverage

Frequently Asked Questions

What does AtriCure do?

AtriCure, Inc. is a medical device company focused on surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management.

What is the ATRC stock price target?

The Wall Street consensus 12-month price target for ATRC is $64.89.